Black Diamond Therapeutics Q3 2026 Results: Net Loss of $10M, Loss Widens
Black Diamond Therapeutics reported total assets of $115.6 million as of September 30, 2026, a decrease from $143.0 million at year-end 2025. The company is focused on advancing its lead candidate silevertinib toward Phase 3 trials and managing its partnership with Servier Pharmaceuticals for BDTX-4933.
- Key figure
- Net loss $10M